Cargando…

Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer

PURPOSE: The current treatment methods available for advanced gastric cancer are not very promising. Hence, it is important to explore novel biomarkers and potential therapeutic agents to treat gastric cancer (GC). This study aimed to identify hub genes associated with GC prognosis and explore poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shiyu, Xiang, Xuelian, Liu, Li, Yang, Huiying, Cen, Dongliang, Tang, Guodu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643151/
https://www.ncbi.nlm.nih.gov/pubmed/34876855
http://dx.doi.org/10.2147/CMAR.S341485
_version_ 1784609822683955200
author Zhang, Shiyu
Xiang, Xuelian
Liu, Li
Yang, Huiying
Cen, Dongliang
Tang, Guodu
author_facet Zhang, Shiyu
Xiang, Xuelian
Liu, Li
Yang, Huiying
Cen, Dongliang
Tang, Guodu
author_sort Zhang, Shiyu
collection PubMed
description PURPOSE: The current treatment methods available for advanced gastric cancer are not very promising. Hence, it is important to explore novel biomarkers and potential therapeutic agents to treat gastric cancer (GC). This study aimed to identify hub genes associated with GC prognosis and explore potential drugs for its treatment. MATERIALS AND METHODS: Three gene expression data of GC and normal tissues were downloaded from the Gene Expression Omnibus (GEO) and processed to identify the differentially expressed genes (DEGs). We conducted a comprehensive analysis of DEGs, including functional enrichment analysis, construction of protein–protein interaction (PPI) network, identification of hub genes, survival analysis and expression verification of hub genes. Finally, we constructed the network of miRNA–mRNA, and predicted the drugs that might be effective for GC treatment. RESULTS: A total of 340 DEGs, including 94 up-regulated and 246 down-regulated genes, were identified. Among the up-regulated DEGs, the enrichment terms were primarily related to tumorigenesis and tumor progression, extracellular matrix organization, and collagen catabolic process. Additionally, 10 hub genes (FN1, COL3A1, COL1A2, BGN, THBS2, COL5A2, THBS1, COL5A1, SPARC, and COL4A1) were identified, out of which 7 genes were significantly associated with poor overall survival (OS) in GC. The expression levels of these 7 hub genes were verified using real-time PCR, immunohistochemistry, and the GEPIA2 (Gene Expression Profiling Interactive Analysis) server. A regulatory network of miRNA–mRNA was also constructed, and the top 4 interactive miRNAs (hsa-miR-29b-3p, hsa-miR-140-3p, hsa-miR-29a-3p, and hsa-miR-29c-3p) that targeted the most hub genes were identified. Finally, fourteen small molecules were predicted to be effective in treating GC. CONCLUSION: The identification of the hub genes, miRNA–mRNA network, and potential candidate drugs associated with GC provides new insights into the molecular mechanisms and treatment of GC.
format Online
Article
Text
id pubmed-8643151
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86431512021-12-06 Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer Zhang, Shiyu Xiang, Xuelian Liu, Li Yang, Huiying Cen, Dongliang Tang, Guodu Cancer Manag Res Original Research PURPOSE: The current treatment methods available for advanced gastric cancer are not very promising. Hence, it is important to explore novel biomarkers and potential therapeutic agents to treat gastric cancer (GC). This study aimed to identify hub genes associated with GC prognosis and explore potential drugs for its treatment. MATERIALS AND METHODS: Three gene expression data of GC and normal tissues were downloaded from the Gene Expression Omnibus (GEO) and processed to identify the differentially expressed genes (DEGs). We conducted a comprehensive analysis of DEGs, including functional enrichment analysis, construction of protein–protein interaction (PPI) network, identification of hub genes, survival analysis and expression verification of hub genes. Finally, we constructed the network of miRNA–mRNA, and predicted the drugs that might be effective for GC treatment. RESULTS: A total of 340 DEGs, including 94 up-regulated and 246 down-regulated genes, were identified. Among the up-regulated DEGs, the enrichment terms were primarily related to tumorigenesis and tumor progression, extracellular matrix organization, and collagen catabolic process. Additionally, 10 hub genes (FN1, COL3A1, COL1A2, BGN, THBS2, COL5A2, THBS1, COL5A1, SPARC, and COL4A1) were identified, out of which 7 genes were significantly associated with poor overall survival (OS) in GC. The expression levels of these 7 hub genes were verified using real-time PCR, immunohistochemistry, and the GEPIA2 (Gene Expression Profiling Interactive Analysis) server. A regulatory network of miRNA–mRNA was also constructed, and the top 4 interactive miRNAs (hsa-miR-29b-3p, hsa-miR-140-3p, hsa-miR-29a-3p, and hsa-miR-29c-3p) that targeted the most hub genes were identified. Finally, fourteen small molecules were predicted to be effective in treating GC. CONCLUSION: The identification of the hub genes, miRNA–mRNA network, and potential candidate drugs associated with GC provides new insights into the molecular mechanisms and treatment of GC. Dove 2021-11-30 /pmc/articles/PMC8643151/ /pubmed/34876855 http://dx.doi.org/10.2147/CMAR.S341485 Text en © 2021 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Shiyu
Xiang, Xuelian
Liu, Li
Yang, Huiying
Cen, Dongliang
Tang, Guodu
Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer
title Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer
title_full Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer
title_fullStr Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer
title_full_unstemmed Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer
title_short Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer
title_sort bioinformatics analysis of hub genes and potential therapeutic agents associated with gastric cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643151/
https://www.ncbi.nlm.nih.gov/pubmed/34876855
http://dx.doi.org/10.2147/CMAR.S341485
work_keys_str_mv AT zhangshiyu bioinformaticsanalysisofhubgenesandpotentialtherapeuticagentsassociatedwithgastriccancer
AT xiangxuelian bioinformaticsanalysisofhubgenesandpotentialtherapeuticagentsassociatedwithgastriccancer
AT liuli bioinformaticsanalysisofhubgenesandpotentialtherapeuticagentsassociatedwithgastriccancer
AT yanghuiying bioinformaticsanalysisofhubgenesandpotentialtherapeuticagentsassociatedwithgastriccancer
AT cendongliang bioinformaticsanalysisofhubgenesandpotentialtherapeuticagentsassociatedwithgastriccancer
AT tangguodu bioinformaticsanalysisofhubgenesandpotentialtherapeuticagentsassociatedwithgastriccancer